Diabetic retinopathy is the leading cause of preventable blindness in the U.S — yet far too few people who need screening actually receive it. Through his company, Digital Diagnostics, and its flagship product LumineticsCore, Michael and his team have built an FDA-authorized autonomous AI system that brings diabetic retinopathy screening much closer to patients.

In this episode, we discuss how Michael has spent over a decade driving the systemic changes needed to make autonomous AI viable clinically, economically, and ethically.

From a farm in rural Kentucky to the cutting edge of molecular biology, Phil Sharp’s path is anything but ordinary. In 1977, he discovered RNA splicing at MIT—a breakthrough that redefined biology and won him a Nobel Prize. But his story goes beyond science—it’s also the story of how the biotech industry was born.

In this episode, we explore:

• How did he go from a rural farm in Kentucky to a Nobel prize-winning discovery at MIT?
• How did the city of Cambridge become the most concentrated biotech ecosystem in the world?
• How to build trust in technology today, just as biotech had to build trust around recombinant DNA in the 1970s?

From radiology to the forefront of AI health regulation , Dr. Hugh Harvey has unique insights into the intersection between health, AI, and regulation - as well as some hot takes.

Among other topics, we explored:

• Why is there not more adoption of AI despite all the hype around it?
• What are some misconceptions that companies have about the regulatory process?
• Should we always have a human a loop?